534 related articles for article (PubMed ID: 26405808)
1. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
Shi H; Cheng Q; Yuan S; Ding X; Liu Y
Chemistry; 2015 Nov; 21(46):16547-54. PubMed ID: 26405808
[TBL] [Abstract][Full Text] [Related]
2. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery.
Zheng YR; Suntharalingam K; Johnstone TC; Yoo H; Lin W; Brooks JG; Lippard SJ
J Am Chem Soc; 2014 Jun; 136(24):8790-8. PubMed ID: 24902769
[TBL] [Abstract][Full Text] [Related]
3. Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug.
Ravera M; Gabano E; Bonzani D; Zanellato I; Arrais A; Cantamessa S; Biggiogera M; Osella D
J Inorg Biochem; 2018 Dec; 189():185-191. PubMed ID: 30312905
[TBL] [Abstract][Full Text] [Related]
4. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
[TBL] [Abstract][Full Text] [Related]
5. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
[TBL] [Abstract][Full Text] [Related]
6. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
Yu C; Ding B; Zhang X; Deng X; Deng K; Cheng Z; Xing B; Jin D; Ma P; Lin J
Biomaterials; 2018 Feb; 155():112-123. PubMed ID: 29175080
[TBL] [Abstract][Full Text] [Related]
7. Advances in platinum chemotherapeutics.
Harper BW; Krause-Heuer AM; Grant MP; Manohar M; Garbutcheon-Singh KB; Aldrich-Wright JR
Chemistry; 2010 Jun; 16(24):7064-77. PubMed ID: 20533453
[TBL] [Abstract][Full Text] [Related]
8. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
9. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles.
Min Y; Li J; Liu F; Yeow EK; Xing B
Angew Chem Int Ed Engl; 2014 Jan; 53(4):1012-6. PubMed ID: 24311528
[TBL] [Abstract][Full Text] [Related]
10. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
Yue Z; Wang H; Li Y; Qin Y; Xu L; Bowers DJ; Gangoda M; Li X; Yang HB; Zheng YR
Chem Commun (Camb); 2018 Jan; 54(7):731-734. PubMed ID: 29303526
[TBL] [Abstract][Full Text] [Related]
11. An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects.
Hernández-Gil J; Cobaleda-Siles M; Zabaleta A; Salassa L; Calvo J; Mareque-Rivas JC
Adv Healthc Mater; 2015 May; 4(7):1034-42. PubMed ID: 25846677
[TBL] [Abstract][Full Text] [Related]
12. Cyclodextrin capped gold nanoparticles as a delivery vehicle for a prodrug of cisplatin.
Shi Y; Goodisman J; Dabrowiak JC
Inorg Chem; 2013 Aug; 52(16):9418-26. PubMed ID: 23889547
[TBL] [Abstract][Full Text] [Related]
13. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.
Chen Q; Yang Y; Lin X; Ma W; Chen G; Li W; Wang X; Yu Z
Chem Commun (Camb); 2018 May; 54(42):5369-5372. PubMed ID: 29744485
[TBL] [Abstract][Full Text] [Related]
14. Unique Use of Alkylation for Chemo-Redox Activity by a Pt(IV) Prodrug.
Pathak RK; Dhar S
Chemistry; 2016 Feb; 22(9):3029-36. PubMed ID: 26807548
[TBL] [Abstract][Full Text] [Related]
15. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
16. Human transport protein carrier for controlled photoactivation of antitumor prodrug and real-time intracellular tumor imaging.
Li X; Mu J; Liu F; Tan EW; Khezri B; Webster RD; Yeow EK; Xing B
Bioconjug Chem; 2015 May; 26(5):955-61. PubMed ID: 25938732
[TBL] [Abstract][Full Text] [Related]
17. Platinum (IV)-coordinate polymers as intracellular reduction-responsive backbone-type conjugates for cancer drug delivery.
Yang J; Liu W; Sui M; Tang J; Shen Y
Biomaterials; 2011 Dec; 32(34):9136-43. PubMed ID: 21889206
[TBL] [Abstract][Full Text] [Related]
18. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
Ravera M; Gabano E; Zanellato I; Perin E; Arrais A; Osella D
Dalton Trans; 2016 Nov; 45(43):17233-17240. PubMed ID: 27722707
[TBL] [Abstract][Full Text] [Related]
19. A core cross-linked polymeric micellar platium(IV) prodrug with enhanced anticancer efficiency.
Hou J; Shang J; Jiao C; Jiang P; Xiao H; Luo L; Liu T
Macromol Biosci; 2013 Jul; 13(7):954-65. PubMed ID: 23744619
[TBL] [Abstract][Full Text] [Related]
20. Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.
Huo S; Shen S; Liu D; Shi T
J Phys Chem B; 2012 Jun; 116(22):6522-8. PubMed ID: 22574871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
